Type 1 diabetes mellitus (T1D) represents roughly 5 - 10% of all diabetic patients. Prevalence of this pathology points that > 500,000 children suffer from T1D globally, that are located mostly in North America as well as Europe [1]. But the epidemiology points that the incidence of T1D has escalated rapidly in recent years [2]. In 2017, the International Diabetes Federation (IDF) declared 132,600 newly diagnosed T1D cases all over the world. It is predicted that incidence of T1D in ≤ 5yr age will increase 2 fold in less than 20yrs

References

1. Patterson C., et al. “Diabetes in the young - A global view and worldwide estimates of number of children with type 1 diabetes”. Diabetes Research and Clinical Practice 103 (2014): 161-175.
2. Maahs DM., et al. “Epidemiology of type 1 diabetes”. Endocrinology and Metabolism Clinics of North America 39 (2010): 481-497.
3. Patterson CC., et al. “Incidence trends for childhood Type 1 Diabetes in Europe during 1989-2003 and predicted new cases 2005-20:a multicentre prospective registration study”. Lancet 9860 (2009): 2027-2033.
4. Kulvinder Kochar Kaur., et al. “An update on the Immunotherapy Strategies for the treatment of Type 1 Diabetes (TID)-How far have we reached in reaching insulin independency in TID therapy-A Systematic Review’’. Journal of Endocrinology (2020).
5. Wallberg M and Cooke A. “Immune mechanisms in Type 1 Diabetes”. Trends in Immunology 12 (2013): 583-591.
6. Knip M and Smell O. “Environmental triggers of Type 1 Diabetes”. Cold Spring Harbor Perspectives in Medicine 7 (2012): 176-185.
7. Adamczak DM., et al. “The roll of Toll like receptors and Vitamin D in Diabetes mellitus Type 1-a review”. Scandinavian Journal of Immunology 2 (2014): 75-84.
8. Norris JM., et al. “Timing of initial cereal exposure in infancy and risk of islet autoimmunity”. The Journal of the American Medical Association 13 (2003): 1713-1720.
9. Itoh A and Ridgway WM. “Targeting innate immunity to downregulate adaptive immunity and reverse Type 1 Diabetes and reverse Type 1 Diabetes”. ImmunoTargets and Therapy 6 (2017): 31-38.
10. Kondrashova A and Hyoty H. “Role of viruses and other microbes in the pathogenesis of Type 1 Diabetes”. International Reviews of Immunology 4 (2014): 284-295.
11. Mojlibian M., et al. “Diabetes specific HLA-DR-restricted proinflammatory T cell response to wheat polypeptides in tissue transglutaminase antibody –negative patients with Type 1 Diabetes”. Diabetes8 (2009): 1789-1796.
12. Adorini L. “Interventions in autoimmunity: the potential of Vitamin D receptor agonists”. Cellular Immunology2 (2005): 115-124.
13. Knip M. “Autoimmune mechanism s in Type 1 Diabetes”. Autoimmunity Reviews 7 (2008): 550-557.
14. Zhou Z and Jensen PE. “Structural characteristics of HLA-DQ that may impact DM editing and susceptibility to Type 1 Diabetes”. Frontiers in Immunology 4 (2013): 262.
15. Wing K., et al. “CTLA-4 control over Foxp3+regulatory T cell function”. Science 5899 (2008): 271-275.
16. Roy Chaudhary R., et al. “BACH2 represses effector programs to stabilize Treg- mediated Immune homeostasis”. Nature7455 (2013): 506-510.
17. Downes K., et al. “Reduced expression of ifih1 is protective for Type 1 Diabetes”. PLoS One9 (2010): e12469.
18. Wachlin G., et al. “IL-1β, IFNƴ and TNFα increase vulnerability of pancreatic beta cells to autoimmune destruction”. Journal of Autoimmunity 4 (2003): 303-312.
19. Marroqli L., et al. “BACH2-a candidate risk gene for Type 1 Diabetes, regulates apoptosis in pancreatic β-cells via JNK 1 modulation and crosstalk with the candidate gene PTPN2”. Diabetes 7 (2014): 2516-2527.
20. Naguiera TC., et al. “GLIS3.a susceptibility gene for Type 1 and type2 Diabetes modulates pancreatic β-cells apoptosis via regulation of a splice variant of the BH3-Only protein bim”. PLoS Genetics5 (2013): e1003532.
21. Elsby LM., et al. “Functional evaluation of TNFAIP3(A20) in rheumatoid arthritis”. Clinical and Experimental Rheumatology 5 (2010): 708-714.
22. Orban T., et al. “A novel quantitative approach to staging and assessing recovery from type 1 diabetes mellitus: the type 1 diabetes mellitus metabolic recovery index”. International Journal of Molecular Sciences 21 (2020): 992.
23. Saberzadeh-Ardestani B., et al. “Type 1 Diabetes: Cellular and Molecular Pathophysiology at a glance”. Cell Journal 3 (2018): 294-301.

Citation

Citation: Kulvinder Kochar Kaur. “Attempting Getting Insulin Independent Immunotherapies in Type 1 Diabetes Mellitus (T1D) in the Pre Stage 1 (Before Islet Autoantibodies)”. Acta Scientific Paediatrics 3.6 (2020): 01-04.

Copyright

Copyright: © 2020 Kulvinder Kochar Kaur. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.